查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573713

衣原体感染诊断市场、机会、成长动力、产业趋势分析与预测，2024-2032

Chlamydia Infection Diagnostics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 100 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球衣原体感染诊断市场估值为 15 亿美元。

即时检测 (POC) 检测对于检测沙眼衣原体至关重要，具有高灵敏度和特异性。向分子诊断的转变强调了对准确、及时的感染识别、减少併发症和传播风险的需求。

由于患者对便利性和隐私的偏好，家庭检测套件呈上升趋势。多重检测等创新技术能够同时检测多种性传染感染 (STI)，因其效率和成本效益而变得越来越受欢迎。公共卫生运动和教育措施提高了意识并促进定期检查，进一步推动市场成长。

政府措施也促进了市场扩张。例如，2021 年 6 月，英国政府在其国家衣原体筛检计画 (NCSP) 中重点关注女性，并认识到她们发生严重感染结果的风险较高。此举旨在为 25 岁以下性活跃的女性提供快速治疗并扩大社区检测。

整个衣原体感染诊断产业根据测试类型、感染类型、最终用途和地区进行分类。

2023 年，核酸扩增测试 (NAAT) 领域凭藉其无与伦比的灵敏度和特异性引领市场，产生约 6.683 亿美元的收入。它们能够检测最低限度的沙眼衣原体 DNA 水平，确保准确的感染识别。这种准确性减少了误报，保证了更可靠的诊断。鑑于许多衣原体感染，尤其是女性衣原体感染，是无症状的，NAAT 确定这些病例的能力对于早期干预、预防骨盆腔炎和不孕症等併发症至关重要。 NAAT 通常在数小时内即可提供快速结果，这对于及时诊断和治疗至关重要。这种速度增强了患者管理并减少了感染传播。

2023 年，医院将成为市场的主导部分，预计在预测期内将实现 7.4% 的强劲成长率。医院配备了尖端的诊断技术和实验室，可以进行各种测试，包括 NAAT 和其他分子诊断。这种全面的基础设施使医院能够提供精确、高效的衣原体检测，巩固其市场主导地位。由于患者流动率很高，包括那些有性传染感染症状或进行常规筛检的患者，医院强大的诊断能力使他们成为衣原体诊断的主要使用者。提供全方位方法（诊断、治疗和随访）的医院可提高患者的便利性并确保护理的连续性，使其成为衣原体检测的首选场所。

2023年，北美衣原体感染诊断市场收入为5.881亿美元，预计未来几年将大幅成长。尤其是美国，它是世界上衣原体感染率最高的国家之一，这刺激了对有效诊断解决方案的需求。疾病预防控制中心等组织倡导定期筛检和早期衣原体检测。他们的倡议，从针对 25 岁以下人群的常规筛检到针对高风险族群的针对性计划，扩大了对诊断测试的需求。在强调性传染感染检测和现代诊断工具重要性的宣传活动的推动下，人们对性传染感染及其健康影响的认识和教育不断提高，正在提高检测率并推动市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 披衣菌感染盛行率上升
      • 诊断技术的进步
      • 越来越多地采用家庭检测套件
      • 政府措施和资金的增加
    • 产业陷阱与挑战
      • 低收入和中等收入国家缺乏认识
      • 社会耻辱与保密问题
  • 成长潜力分析
  • 监管环境
  • 未来市场趋势
  • 技术景观
  • 波特的分析
  • PESTEL分析
  • 差距分析
  • 产品管道分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按测试类型，2021 - 2032 年

  • 主要趋势
  • 核酸扩增检验（NAAT）
  • 血清学检测
  • 直接萤光抗体检测
  • 文化测试
  • 其他测试类型

第 6 章：市场估计与预测：按感染类型，2021 - 2032 年

  • 主要趋势
  • 生殖器衣原体感染
  • 直肠披衣菌感染
  • 眼衣原体感染

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 专科诊所
  • 诊断中心

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Abbott
  • BD
  • Bio-Rad Laboratories, Inc.
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • QuidelOrtho Corporation.
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech Plc.
简介目录
Product Code: 11042

The Global Chlamydia Infection Diagnostics Market was valued at USD 1.5 billion in 2023. Projections indicate a growth trajectory, with an anticipated CAGR of 7.1% from 2024 to 2032, driven by technological advancements, heightened awareness, and shifting healthcare demands.

Point-of-care (POC) tests are pivotal in detecting Chlamydia trachomatis, boasting high sensitivity and specificity. The shift towards molecular diagnostics underscores the demand for precise and timely infection identification, reducing complications and transmission risks.

There's a rising trend in home-based testing kits due to patients' preference for convenience and privacy. Innovations like multiplex assays, which enable simultaneous detection of multiple sexually transmitted infections (STIs), are becoming popular for their efficiency and cost-effectiveness. Public health campaigns and educational initiatives boost awareness and promote regular screenings, further propelling market growth.

Government initiatives also bolster market expansion. For instance, in June 2021, the U.K. government spotlighted women in its National Chlamydia Screening Programme (NCSP), recognizing their heightened risk of severe infection outcomes. This move aims to fast-track treatment and expand community testing for sexually active women under 25.

The overall Chlamydia infection diagnostics industry is classified based on test type, type of infections, end-use, and region.

In 2023, the nucleic acid amplification test (NAAT) segment led the market, generating approximately USD 668.3 million in revenues, owing to their unmatched sensitivity and specificity. Their capability to detect minimal Chlamydia trachomatis DNA levels ensures accurate infection identification. This accuracy diminishes false negatives, guaranteeing more dependable diagnoses. Given that many chlamydia infections, especially in women, are asymptomatic, NAATs' ability to pinpoint these cases is vital for early intervention, preventing complications like pelvic inflammatory disease and infertility. NAATs deliver swift results, often within hours, crucial for prompt diagnosis and treatment. This rapidity enhances patient management and curtails infection spread.

In 2023, hospitals emerged as the dominant segment in the market, with projections indicating a robust growth rate of 7.4% during the forecast period. Equipped with cutting-edge diagnostic technologies and laboratories, hospitals can conduct a diverse array of tests, including NAATs and other molecular diagnostics. This comprehensive infrastructure empowers hospitals to deliver precise and efficient chlamydia testing, solidifying their market prominence. With a high patient turnover, including those with STI symptoms or routine screenings, hospitals' robust diagnostic capabilities position them as primary users of chlamydia diagnostics. Offering an all-encompassing approach-diagnosis, treatment, and follow-up-hospitals enhance patient convenience and ensure care continuity, making them the preferred venue for chlamydia testing.

In 2023, North America accounted for a revenue of USD 588.1 million in the chlamydia infection diagnostics market, with expectations of significant growth in the coming years. The U.S., in particular, grapples with one of the world's highest chlamydia infection rates, spurring a demand for effective diagnostic solutions. Organizations like the CDC champion regular screenings and early chlamydia detection. Their initiatives, from routine screenings for those under 25 to targeted programs for high-risk groups, amplify the demand for diagnostic tests. Heightened awareness and education surrounding STIs and their health ramifications, bolstered by campaigns emphasizing the significance of STI testing and modern diagnostic tools, are driving up testing rates and fueling market growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chlamydia infections
      • 3.2.1.2 Advancements in diagnostic technologies
      • 3.2.1.3 Growing adoption of home testing kits
      • 3.2.1.4 Increase in government initiatives and funding
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Lack of awareness in low and middle-income countries
      • 3.2.2.2 Social stigma and confidentiality concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Technological landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Gap analysis
  • 3.10 Product pipeline analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2023
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Nucleic acid amplification test (NAAT)
  • 5.3 Serology test
  • 5.4 Direct fluorescent antibody test
  • 5.5 Culture test
  • 5.6 Other test types

Chapter 6 Market Estimates and Forecast, By Type of Infections, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Genital chlamydia infection
  • 6.3 Rectal chlamydia infection
  • 6.4 Ocular chlamydia infection

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Specialty clinics
  • 7.4 Diagnostic centres

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 BD
  • 9.3 Bio-Rad Laboratories, Inc.
  • 9.4 DiaSorin S.p.A.
  • 9.5 F. Hoffmann-La Roche Ltd
  • 9.6 Hologic, Inc.
  • 9.7 QuidelOrtho Corporation.
  • 9.8 Siemens Healthineers
  • 9.9 Thermo Fisher Scientific Inc.
  • 9.10 Trinity Biotech Plc.